Application of growth models to South African Boer goat castrates and does under feedlot conditions.

Mathematical models may aid researchers in describing biological processes, like growth, in animals. This study aimed to collect the body weight data of 18 Boer goat castrates and 20 Boer goat does, from birth until maturity, to model growth and determine growth trends. This is a novel investigation as sufficient information on an age-weight database for these two Boer goat sexes from birth to maturity, is lacking. Using age-weight data, four nonlinear models, namely the Brody, Gompertz, Logistic and Von Bertalanffy growth models, were plotted and evaluated. The model parameters of each growth model were compared for differences between the two sexes. The statistical effectiveness of fit was determined for each model using AIC and RMSE, with R2 also being considered. All models except the Brody model, predicted significantly heavier mature weights for castrates. The Brody model was deemed unfit to describe Boer goat growth as the function severely over-predict weights from birth until maturity for both sexes. The Von Bertalanffy (R2 = 91.3) and Gompertz functions (R2 = 91.3) showed the best fit for Boer goat castrates, while the Gompertz model (R2 = 95.1) showed the best fit for Boer goat does. The Gompertz function is the preferred model to depict Boer goat growth overall, as it accurately characterized growth of both sexes. According to the Gompertz model the age at which the inflection point of the growth curve was reached, did not differ significantly between castrates and does (141.80 days versus 136.31 days). There was also no significant difference in maturation rate between the two sexes.

Wool production and quality traits of pure- and crossbred Merino-type sheep.

Very little information is available on the quality of wool produced by terminal crosses out of wool producing dam lines. This study was therefore undertaken to elucidate the wool quality traits of four crossbred lines relative to Merinos and Dohne Merinos, which served as dam lines. Each dam line was mated to rams of their own breed as well as to Dormer or Ile de France rams to create four crossbred lines, namely, Dohne x Dormer, Dohne x Ile de France, Merino x Dormer, and Merino x Ile de France, in addition to the purebred Dohne Merino and Merino lines. Four rams and four ewes from each of these lines were reared up to one year of age under optimal growth conditions and shorn at the end of that time. Fleeces were weighed and samples collected for analysis. Neither sex nor genotype influenced clean fleece weight or clean yield percentage, but fibre diameter differed between genotypes. Purebred Merino had the finest wool (18.26 µm) and the Merino x Dormer cross the coarsest (26.01 µm). However, all lines still produced wool that could be used in manufacturing clothing, while fleeces showed good uniformity. The two purebred lines had the highest comfort factor (> 98%). The crossbred lines produced a similar quantity of wool as the purebreds, although of poorer quality. All genotypes except Merino x Dormer appear to produce wool that could be processed into garments, although the crossbred wool would only be suitable for outerwear.

Modelling and predicting fat deposition rates in various South African sheep crosses using ultrasound technology.

Producers require an accurate predictive tool that can determine the optimal point of slaughter based on fat depth. The modelling of fat deposition with a simple mathematical model could supply in this need. Dohne Merino and Merino ewes were crossed with Dorper, Dormer and Ile de France rams or rams of their own breeds to create two purebred (Dohne Merino and Merino) and six crossbred groups (Dohne x Dorper, Dohne x Dormer, Dohne x Ile de France, Merino x Dorper, Merino x Dormer and Merino x Ile de France) of offspring. Fat deposition of four lambs of each sex per genotypic group was monitored from 80 to 360 days using ultrasound, and the data subsequently fitted to various equations and evaluated for goodness of fit. A linear fitting of fat depth to age (R2 > 0.77) and live weight (R2 > 0.56) were deemed to provide the best fit. The slope parameters of the equations indicated that ewes deposited fat faster than rams and that Dorper crosses had the highest fat deposition rate. An attempt was also made to model loin muscle growth, but the model fit was judged to be unsatisfactory. The predictive models developed here are deemed suitable for inclusion in feedlot management systems to aid in the production of optimally classified lamb carcasses.

Determining and predicting feed intake in crossbred sheep from weaning until maturity.

Access to simple, accurate feed intake models would facilitate decision-making in feedlots as feed costs are a major part of operational expenditure. This study aimed to develop genotype-specific feed intake models for South African feedlot lambs. Four ram and four ewe lambs each of eight genotypes were raised under ideal growth conditions from weaning until 1 year of age. Feed intake and growth were monitored throughout this period. The intake data were then used to fit various models to predict daily feed intake, intake as percentage of body weight, cumulative intake and feed conversion ratio. No satisfactory univariate models could be found for the prediction of daily or percentage intake, but a good fit was found for cumulative intake data (R2 >0.80, P <0.01). The slope parameters of these linear models show a strong correlation (72%) with feed conversion and can therefore also serve as proxies for feed conversion. A model was also developed that can predict feed conversion ratio with a moderate accuracy (R2 =0.5, P <0.05) at a given body weight. The cumulative intake model was deemed accurate and simple enough for practical use.

Primary sclerosing cholangitis, Crohn's disease and HLA-B27 in black South African women.

Crohn's disease is rare in South African black people and primary sclerosing cholangitis (PSC) is also rare in black patients with IBD, from South Africa. The presence of HLA-B27 is generally associated with seronegative spondylo-arthropathies and correlates with the occurrence of ankylosing spondylitis, recurrent mouth ulcers and uveitis, in patients with IBD. We describe two women with the combination of Crohn's disease, PSC and HLA-B27 from our cohort of the last 5 years of three black patients with Crohn's disease. Crohn's disease, PSC and HLA-B27 respectively, occur rarely in black South Africans and their concurrent presence in two black women suggests a pathogenetic link of HLA-B27 between Crohn's disease and PSC in this population. Female gender might be an additional determinant in this setting.

Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study.

BACKGROUND AND AIM: The aim of this study was to compare the efficacy and tolerability of low dose pantoprazole (20 mg) (a gastric proton pump inhibitor) with standard dose ranitidine (300 mg) (a histamine-receptor antagonist), in their ability to relieve symptoms and heal oesophageal lesions associated with gastrooesophageal reflux disease (GORD). METHODS: Patients with endoscopically established mild GORD (stage I, modified Savary-Miller classification) were enrolled into a multicentre, randomized, double-blind, parallel-group comparison study (intention-to-treat population, n = 201; age range, 18-82 years). Patients took either oral pantoprazole 20 mg in the morning (n = 101) or ranitidine 300 mg in the evening (n = 100) once daily for 4 weeks or, if the healing was not complete, 8 weeks. Relief from key symptoms (heartburn, acid regurgitation, pain on swallowing) was assessed after 2, 4, and if applicable, 8 weeks. Healing of lesions was confirmed endoscopically after 4 and, if applicable, 8 weeks. RESULTS: Complete relief from key symptoms was noted after 2 weeks in 70/88 (80%) patients treated with pantoprazole vs 45/89 (51%) patients treated with ranitidine ('per-protocol and key-point available' populations, P < 0.001); the corresponding results after 4 weeks were 77/88 (88%) vs 51/88 (58%) (P < 0.001). Complete healing of lesions after 4 weeks of treatment was seen in 74/88 (84%) vs 49/89 (55%) in the pantoprazole and ranitidine group, respectively (P < 0.001, per-protocol); by week 8 the cumulative healing rates were 84/88 (95%) vs 69/89 (78%) in the pantoprazole and ranitidine group, respectively (P < 0.001). For the intention-to-treat populations, the corresponding values for healing after 4 and 8 weeks were 73% vs 49% (P < 0.001) and 83% vs 69% (P < 0.05), respectively. Both study medications were well tolerated. CONCLUSION: Compared to ranitidine 300 mg, the regimen with pantoprazole 20 mg provides faster relief from symptoms and is significantly more effective in healing of oesophageal lesions in patients with mild reflux-oesophagitis. Thus, the low dose of pantoprazole offers a treatment approach which minimizes drug exposure and costs while retaining high efficacy.

Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up.

BACKGROUND: Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+, K+-ATPase, necessary for the final step in gastric acid secretion. AIM: To assess safety and efficacy of oral pantoprazole (40 mg o.d.) used as a prophylaxis against relapse in patients with healed reflux oesophagitis during an open-label, 2-year study. METHODS: Outpatients (n=157) with healed stage II or III reflux oesophagitis (Savary-Miller classification) were enrolled into a long-term, multicentre maintenance study. Endoscopy was performed at entry into the study, after 12 and 24 months, or when disease-specific symptoms occurred on more than three consecutive days. Symptoms were assessed at 3-monthly intervals. Endoscopically confirmed relapses (at least stage I) were evaluated as treatment failures. RESULTS: Of the 178 adverse events, experienced by 88 (56%) patients (intention-to-treat population), 12 (7%) were assessed by the investigators as possibly related to the study medication. Median serum gastrin levels increased from a baseline of 46 ng/L to 90 ng/L, reaching a plateau after 9 months. For the intention-to-treat population the endoscopic remission rates after 12 and 24 months were 87% and 76%, respectively (Life-Table survival analysis, Kaplan-Meier). CONCLUSION: Pantoprazole 40 mg proved to be safe and efficacious during a 2-year prophylaxis treatment in patients with healed reflux oesophagitis.

Evaluation of reflux oesophagitis with technetium-99m-labelled sucralfate.

UNLABELLED: Sucralfate binds with denuded protein to form a stable complex to protect the damaged mucosa. By utilising this property, technetium-99m-labelled sucralfate can be used to demonstrate ulceration in the upper gastro-intestinal tract. AIM: The aim of this study was to evaluate 99mTc-labelled sucralfate in the diagnosis of grade II-III reflux oesophagitis. METHODS: Ten patients with endoscopic proof of grade II-III reflux oesophagitis and 10 patients with normal findings on oesophagoscopy were evaluated after they had swallowed 5 ml 99mTc sucralfate. Radionuclide imaging was done until activity in the oesophagus had ceased. RESULTS: Retention of activity from 10 minutes up to 1 1/2 hours could be demonstrated in 9 patients with endoscopically proven oesophagitis. In the control group complete clearance of activity was seen in 7 patients. Gastro-oesophageal reflux could be demonstrated in 4 patients. CONCLUSION: In conclusion we found 99mTc sucralfate to be a sensitive and specific method for the non-invasive diagnosis of grade II or grade III oesophagitis when compared with endoscopy [corrected].

Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis.

BACKGROUND: Pantoprazole is a substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+, K+-ATPase. METHODS: Pantoprazole 40 mg and 80 mg were compared in a randomized double-blind study in 192 out-patients with stage II or III (Savary-Miller classification) reflux oesophagitis. Patients received either pantoprazole 40 mg (n = 97) or pantoprazole 80 mg (n = 95), once daily before breakfast for 4 weeks. Treatment was extended for a further 4 weeks if the oesophagitis had not healed. RESULTS: After 4 weeks complete healing of the reflux oesophagitis was seen in 78% of protocol-correct patients given pantoprazole 40 mg daily (n = 86), and in 72% in the 80 mg (n = 87) group. The cumulative healing rates after 8 weeks were 95 and 94%, respectively (P > 0.05, Cochran-Mantel-Haenszel), and time until healing of oesophagitis comparable in both groups. Differences between doses were also not significant in an intention-to-treat analysis. Both dosing schedules were well tolerated and the patients experienced remarkable symptom relief. No adverse event or changes in laboratory values of clinical significance could definitely be ascribed to the trial medication. CONCLUSION: The 40 mg pantoprazole dosage is comparable to 80 mg in reflux oesophagitis, both in efficacy and tolerability.